Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03145207 · ClinicalTrials.gov registry record · Early Phase 1
PK and DPK of Lidocaine Dermal Products
A Early Phase 1 study of Heat Effect, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT03145207: Completed Early Phase 1 study of Heat Effect, sponsored by University of Maryland, Baltimore.
NCT03145207 is a Early Phase 1 study of Heat Effect that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 14 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03145207, a Early Phase 1 study of Heat Effect, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a bioequivalence study to compare lidocaine release between a brand name and generic skin patches in healthy adults.
Primary Outcome
maximum (or peak) serum concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered
Conditions Studied
Interventions
- DRUG Lidocaine patch
Study Locations (1)
Maryland
- General Clinical Research Center (GCRC) at the University of - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-12-14 |
| Est. Completion | 2020-05-15 |
| Phase | Early Phase 1 |
What the finished NCT03145207 record still lists
NCT03145207 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Heat Effect appearing as the primary indexed condition, and to 1 intervention - of which Lidocaine patch is the first listed.
NCT03145207 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT03145207 about?
NCT03145207 is a clinical study titled "PK and DPK of Lidocaine Dermal Products". This is a bioequivalence study to compare lidocaine release between a brand name and generic skin patches in healthy adults.
What is the current status of trial NCT03145207?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2016-12-14. Estimated completion is 2020-05-15.
What conditions does trial NCT03145207 study?
This clinical trial studies the following conditions: Heat Effect.
What interventions are being tested in trial NCT03145207?
The interventions under investigation include: Lidocaine patch (DRUG).
Who is sponsoring clinical trial NCT03145207?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03145207 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heat Effect
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03145207's enrollment target sits among peer trials
14 1475th of 2000 higher than 498 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy